Trial Search Results

Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if giving radiation therapy to the head is effective in preventing CNS metastases in patients who have stage III non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying how well radiation therapy to the head works in preventing CNS metastases in patients who have been previously treated for stage III non-small cell lung cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Radiation Therapy Oncology Group

Collaborator: National Cancer Institute (NCI)

Intervention(s):

  • Radiation: Radiation therapy
  • Other: Observation

Phase:

Phase 3

Eligibility


DISEASE CHARACTERISTICS:

   - Diagnosis of stage IIIA or IIIB non-small cell lung cancer

      - Complete response, partial response, or stable disease after definitive
      locoregional therapy (with surgery and/or radiation therapy, with or without
      chemotherapy (chemotherapy alone does not constitute definitive therapy))

         - No more than 16 weeks since prior therapy

   - No progressive disease

   - No extracranial distant metastatic disease

   - No suspicion of CNS metastases by MRI or CT scan

PATIENT CHARACTERISTICS:

Age

   - 18 and over

Performance status

   - Not specified

Life expectancy

   - Not specified

Hematopoietic

   - Not specified

Hepatic

   - Not specified

Renal

   - Not specified

Other

   - No other malignancy within the past 3 years except nonmelanoma skin cancer

   - Not pregnant or nursing

   - Negative pregnancy test

   - Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

   - No concurrent anticancer biologic therapy

Chemotherapy

   - See Disease Characteristics

   - No concurrent anticancer cytotoxic chemotherapy

Endocrine therapy

   - Not specified

Radiotherapy

   - See Disease Characteristics

   - No prior cranial irradiation

Surgery

   - See Disease Characteristics

Other

   - Recovered from all prior therapies

   - No concurrent enrollment on any other phase III study that has progression-free,
   disease-free, or overall survival as an endpoint

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Derek Huang
6507250203
Not Recruiting